The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, May 20, 2025, 12:00 Hrs [IST] GSK plc announced ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM).

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma.

Blenrep combo nearly tripled PFS to 36.6 months vs 13.4 months in DREAMM-7. Blenrep cut risk of death by 42% vs comparator in DREAMM-7 at 39.4-month median follow-up. Feel unsure about the market ...

Investing.com -- GSK plc (LON: GSK ), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...

In DREAMM-8, at a median follow-up of 21.8 months, the median PFS was not yet reached with the Blenrep combination compared to 12.7 months in the bortezomib combination.